| 논문분류 | 춘계학술대회 초록집 |
|---|---|
| 제목 | Impact of Serum β2-microglobulin Levels on Hospitalization for Cardiovascular Diseases or Infection in Chronic Hemodialysis Patients |
| 저자 | Ji Won Min1, Hyung Wook Kim1, Kyung Yoon Chang1, Su-Hyun Kim2, Young Ok Kim1,Dong Chan Jin1, Ho Chul Song1, Euy Jin Choi1, Yong-Lim Kim3,Yon-Su Kim4, Shin-Wook Kang5, Nam-Ho Kim6, Chul Woo Yang1, Yong Kyun Kim1 |
| 출판정보 | 2014; 2014(1): |
| 키워드 | β2-microglobulin, Hemodialysis, Cardiovascular |
| 초록 | ackground: β2-microglobulin is a surrogate marker of middle-molecule uremic toxins and serum β2-microglobulin levels are associated with all-cause mortality in hemodialysis (HD) patients.In this study, we investigated the impact of serum β2-microglobulin levels on cardiovascular and infectious diseases in chronic HD patients. Methods :Prevalent HD patients were selected from the Clinical Research Center registry for End Stage Renal Disease, a multicenter prospective cohort study on dialysis patients in Korea. Patients were categorized into three groups by tertiles of serum β2-microglobulin levels as follows: Tertile 1, β2-microglobulin <23.47 mg/L; Tertile 2, β2-microglobulin 23.47-32.24 mg/L; Tertile 3, β2-microglobulin >32.24 mg/L. Cox regression analysis was used to calculate the adjusted hazard ratio (HR) for first cardiovascular diseases or infection related-hospitalizations. Results: A total of 1,012 prevalent HD patients were included in this study. The median follow-up period was 24 months. Multivariate Cox proportional hazard model showed that highest tertile had significantly increased risk of cardiovascular diseases related-hospitalizations compared with the lowest tertile (HR: 1.68, 95% CI: 1.05-2.67). The risk of infection related-hospitalizations was significantly increased in higher tertiles compared with lowest tertile (Tertile 2; HR 1.66, 95% CI: 1.07-2.58, Tertile 3; 1.88, 95% CI, 1.23-2.88) after adjustment for clinical variables. Conclusions: Our data showed that the serum β2-microglobulin levels were significant predictor of clinical outcome for cardiovascular disease or infection in chronic HD patients. |
| 원문(PDF) | PDF 원문보기 |